Pyloric stenosis due to Crohn's disease

Related Experiment Video

Updated: Oct 28, 2026

Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis
10:41

Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis

Published on: December 15, 2023

H Nakamura1, H Yanai, O Miura

  • 1First Department of Internal Medicine, Yamaguchi University School of Medicine, Kogushi, Ube, Japan.

Journal of Gastroenterology
|October 17, 1998
PubMed

Insights

Corticosteroids effectively reduced pyloric stenosis in a Crohn's disease patient unresponsive to other treatments. This finding offers a potential non-surgical option for managing this rare gastrointestinal complication.

Area of Science:

  • Gastroenterology
  • Inflammatory Bowel Disease
  • Digestive System Disorders

Background:

  • Crohn's disease, a chronic inflammatory condition, can affect the gastroduodenal region, though this is uncommon.
  • Pyloric stenosis, a narrowing of the stomach's exit, is a potential complication of gastroduodenal Crohn's disease.
  • Medical and surgical interventions are considered for pyloric stenosis, with varying success rates.

Observation:

  • A 44-year-old male patient presented with pyloric stenosis attributed to Crohn's disease.
  • The patient's condition was refractory to treatment with a proton-pump inhibitor.
  • Helicobacter pylori infection was ruled out as a causative factor.

Findings:

  • Corticosteroid therapy demonstrated a significant positive impact on reducing the severity of pyloric stenosis.
  • The patient experienced marked improvement following corticosteroid administration.
  • Non-response to proton-pump inhibitors highlights the specific challenges in managing this Crohn's complication.

Implications:

  • Corticosteroids may represent a viable therapeutic option for managing Crohn's disease-induced pyloric stenosis.
  • This case suggests a potential non-surgical approach for patients with refractory gastroduodenal Crohn's disease.
  • Further research is warranted to explore the efficacy and mechanisms of corticosteroid treatment in similar cases.

More Related Videos

Laparoscopic Choledochal Cyst Excision and Roux-en-Y Choledochojejunostomy in Adults04:14

Laparoscopic Choledochal Cyst Excision and Roux-en-Y Choledochojejunostomy in Adults

Published on: February 28, 2025

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...